2445460-16-0
2445460-16-0
Chemical Structure
Eblasakimab
Synonym(s): ASLAN004; CSL-334; MK-6105
- CAS No.: 2445460-16-0
- Formula:N/A
- Molecular Weight:(143.86 kDa)
SMILES: [Eblasakimab]
Biological Activity: Eblasakimab (ASLAN004) is a fully human monoclonal antibody that binds with high affinity to IL-13Rα1 (binds to IL-13Rα1 with a Kd of 453 pM). Eblasakimab reduces neuronal responses to IL-4, IL-13, and their combination. Eblasakimab can be used in research on atopic dermatitis[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Eblasakimab | ≥99.0% | Eblasakimab (ASLAN004) is a fully human monoclonal antibody that binds with high affinity to IL-13Rα1 (binds to IL-13Rα1 with a Kd of 453 pM). Eblasakimab reduces neuronal responses to IL-4, IL-13, and their combination. Eblasakimab can be used in research on atopic dermatitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Jin L, et al. LB1037 Aberrant regulation of protein translation controlled by eukaryotic initiation factor 4F (eIF4F) in the pathogenesis of hidradenitis suppurativa (HS) and associated cutaneous squamous cell carcinoma (cSCC). Journal of Investigative Dermatology. 2022 Aug 1;142(8):B37.
- [2]. Reddy SV, et al. LB1751 Downstream effects of IL-13Rα1 blockade on type 2 inflammation and Th1 immune axis activation in atopic dermatitis. Journal of Investigative Dermatology. 2023 Sep 1;143(9):B26.
- [3]. Okamoto T, et al. LB1036 Artificial intelligence for the automated assessment of psoriasis severity. Journal of Investigative Dermatology. 2022 Aug 1;142(8):B37.
- [4]. Cevikbas F, et al. Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers. Clinical immunology (Orlando, Fla.). 2023 Aug;253:109677.
- [5]. Veverka KA, et al. Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study. J Am Acad Dermatol. 2024 Mar;90(3):504-511.
